Can one targeted drug still work after another fails? new trial aims to find out

NCT ID NCT06263543

Recruiting now Disease control Sponsor: Reshma L. Mahtani, D.O. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing whether the drug sacituzumab govitecan (Trodelvy) can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received another targeted drug called T-DXd. The study will enroll 75 participants and measure how many respond to treatment. The goal is to see if using these drugs in sequence can help control the cancer longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab govitecan (Trodelvy)
What this could lead to: If successful, this could show that sacituzumab govitecan remains effective even after prior treatment with T-DXd, offering a new treatment sequence option for people with this type of breast cancer.
What could go wrong: This is a small, early-phase (Phase 2) study with only 75 participants. It may not show enough benefit, or the drug could cause side effects like diarrhea or low blood cell counts. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER BREAST CANCER HORMONE RECEPTOR POSITIVE BREAST CANCER HUMAN EPIDERMAL GROWTH FACTOR 2 LOW BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

Baptist Health Herbert Wertheim Cancer Institute
RECRUITING

Miami, Florida, 33176, United States
University of Kansas Medical Center
RECRUITING

Fairway, Kansas, 66205, United States
Winship Cancer Institute at Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.